	US 11,718,621 B2
	Tebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of use
Akash Jain, Cambridge, MA (US); Evan Hecker, Cambridge, MA (US); Richard Edwards, Cambridge (GB); and Thierry Bonnaud, Cambridge (GB)
Assigned to SPERO THERAPEUTICS, INC., Cambridge, MA (US)
Filed by SPERO THERAPEUTICS, INC., Cambridge, MA (US)
Filed on Dec. 29, 2020, as Appl. No. 17/136,759.
Application 17/136,759 is a continuation of application No. 16/483,989, granted, now 10,889,587, previously published as PCT/US2018/017067, filed on Feb. 6, 2018.
Claims priority of provisional application 62/455,109, filed on Feb. 6, 2017.
Prior Publication US 2021/0122753 A1, Apr. 29, 2021
Int. Cl. C07D 477/20 (2006.01); A61K 45/06 (2006.01); A61P 31/04 (2006.01)

CPC C07D 477/20 (2013.01) [A61K 45/06 (2013.01); C07B 2200/13 (2013.01)]

16 Claims

1. A crystalline tebipenem pivoxil hydrobromide salt form, wherein the XRPD of the form, obtained from a Cu Kα source, has the characteristic 2θ values of FIG. 21.